CEMIP, acting as a scaffold protein for bridging GRAF1 and MIB1, promotes colorectal cancer metastasis via activating CDC42/MAPK pathway

Xu, Guojie; Zhao, Lei; Hua, Qingling; Wang, Lanqing; Liu, Hongli; Lin, Zhenyu; Jin, Min; Wang, Jing; Zhou, Pengfei; Wu, Gang; Yu, Dandan; Zhang, Dejun; Zhang, Tao

doi:10.1038/s41419-023-05644-z

“…The relationship between CEMIP expression and tumor malignancy has gained signi cant attention, and notable results have been obtained from research on its expression regulation [33][34][35][36][37]. The naturally active compound possesses modulatory properties on signaling pathways involved in various biological activities, making it a potential candidate for application, particularly in the medical eld, as an effective adjunctive therapeutic agent in the treatment of tumors [38][39][40][41][42][43].…”

Section: Discussionmentioning

confidence: 99%

Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway

Sim,

Choe,

Ri

et al. 2023

Preprint

0

View full text Add to dashboard Cite

Osteosarcoma is a malignant bone tumor that is prone to metastasize early and primarily affects children and adolescents. Cell migration-inducing protein (CEMIP) plays a crucial role in the progression and malignancy of various tumor diseases, including osteosarcoma. Chitosan oligosaccharide (COS), an oligomer isolated from chitin, has been found to have significant anti-tumor activity in various cancers. This study investigates the effects of COS on CEMIP expression in osteosarcoma and explores the underlying mechanism. In present study, in vitro experiments were conducted to confirm the inhibitory activity of COS on human osteosarcoma cells. Our results demonstrate that COS possesses inhibitory effects against human osteosarcoma cells and significantly suppresses CEMIP expression in vitro. Next, we studied the inhibition of the expression of CEMIP by COS and then performed bioinformatics analysis to explore the potential inhibitory mechanism of COS against signaling pathways involved in regulating CEMIP expression. Bioinformatics analysis predicted a close association between the PI3K signaling pathway and CEMIP expression and that the inhibitory effect of COS on CEMIP expression may be related to PI3K signaling pathway regulation. The results of this study show that COS treatment significantly inhibits CEMIP expression and the PI3K/AKT/mTOR signaling pathway, as observed both in vitro and in vivo. This study demonstrates that COS could inhibit the expression of CEMIP, which is closely related to osteosarcoma malignancy. This inhibitory effect may be attributed to the inhibition of the PI3K/AKT/mTOR signaling pathway in vitro and in vivo.

show abstract

“…The relationship between CEMIP expression and tumor malignancy has gained significant attention, and notable results have been obtained from research on its expression regulation[ 34 – 38 ]. The naturally active compound possesses modulatory properties on signaling pathways involved in various biological activities, making it a potential candidate for application, particularly in the medical field, as an effective adjunctive therapeutic agent in the treatment of tumors[ 39 – 44 ].…”

Section: Discussionmentioning

confidence: 99%

Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway

Sim,

Choe,

Ri

et al. 2023

Med Oncol

1

0

View full text Add to dashboard Cite

Osteosarcoma is a malignant bone tumor that is prone to metastasize early and primarily affects children and adolescents. Cell migration-inducing protein (CEMIP) plays a crucial role in the progression and malignancy of various tumor diseases, including osteosarcoma. Chitosan oligosaccharide (COS), an oligomer isolated from chitin, has been found to have significant anti-tumor activity in various cancers. This study investigates the effects of COS on CEMIP expression in osteosarcoma and explores the underlying mechanism. In present study, in vitro experiments were conducted to confirm the inhibitory activity of COS on human osteosarcoma cells. Our results demonstrate that COS possesses inhibitory effects against human osteosarcoma cells and significantly suppresses CEMIP expression in vitro. Next, we studied the inhibition of the expression of CEMIP by COS and then performed bioinformatics analysis to explore the potential inhibitory mechanism of COS against signaling pathways involved in regulating CEMIP expression. Bioinformatics analysis predicted a close association between the PI3K signaling pathway and CEMIP expression and that the inhibitory effect of COS on CEMIP expression may be related to PI3K signaling pathway regulation. The results of this study show that COS treatment significantly inhibits CEMIP expression and the PI3K/AKT/mTOR signaling pathway, as observed both in vitro and in vivo. This study demonstrates that COS could inhibit the expression of CEMIP, which is closely related to osteosarcoma malignancy. This inhibitory effect may be attributed to the inhibition of the PI3K/AKT/mTOR signaling pathway in vitro and in vivo.

show abstract

“…Additionally, CEMIP activates CDC42/MAPK pathway-mediated EMT by enhancing GRAF1 degradation. GRAF1 plays an essential role in CEMIP-mediated CRC migration and invasion ( Xu et al, 2023 ).…”

Section: Survey Methodologymentioning

confidence: 99%

The role of CEMIP in cancers and its transcriptional and post-transcriptional regulation

Guo,

Chen

et al. 2024

PeerJ

0

View full text Add to dashboard Cite

CEMIP is a protein known for inducing cell migration and binding to hyaluronic acid. Functioning as a hyaluronidase, CEMIP primarily facilitates the breakdown of the extracellular matrix component, hyaluronic acid, thereby regulating various signaling pathways. Recent evidence has highlighted the significant role of CEMIP in different cancers, associating it with diverse pathological states. While identified as a biomarker for several diseases, CEMIP’s mechanism in cancer seems distinct. Accumulating data suggests that CEMIP expression is triggered by chemical modifications to itself and other influencing factors. Transcriptionally, chemical alterations to the CEMIP promoter and involvement of transcription factors such as AP-1, HIF, and NF-κB regulate CEMIP levels. Similarly, specific miRNAs have been found to post-transcriptionally regulate CEMIP. This review provides a comprehensive summary of CEMIP’s role in various cancers and explores how both transcriptional and post-transcriptional mechanisms control its expression.

show abstract

CEMIP, acting as a scaffold protein for bridging GRAF1 and MIB1, promotes colorectal cancer metastasis via activating CDC42/MAPK pathway

Cited by 7 publications

References 42 publications

Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway

Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway

Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway

The role of CEMIP in cancers and its transcriptional and post-transcriptional regulation

Contact Info

Product

Resources

About